What is it about?
Indacaterol is a novel ultra long-acting bronchodilator that can safely and effectively treat moderate to severe COPD. This paper reviewed studies with 12 weeks of treatment with Indacaterol. We examined the effectiveness of Indacaterol as a treatment considering safety, efficacy and patient perspectives.
Photo by Markus Winkler on Unsplash
Why is it important?
Improvements in patient compliance can vastly improve outcomes. This means a once-daily treatment can equate to an improvement in the quality of care for patients over a twice-daily regime. The 24-hour treatment effect of Indacaterol sets it apart from all other comparators as a step forward in treatment.
Read the Original
This page is a summary of: Comparative efficacy of indacaterol in chronic obstructive pulmonary disease, International Journal of Chronic Obstructive Pulmonary Disease, March 2012, Taylor & Francis, DOI: 10.2147/copd.s19805.
You can read the full text:
The following have contributed to this page